J&J sets out to build a new R&D group af­ter a $1B biotech chris­ten­ing

A siz­able new biotech was born to­day, com­plete with a pub­lic list­ing, pipeline, $1 bil­lion in the bank and ex­pe­ri­enced man­age­ment team all in place. And they have a Big Phar­ma part­ner/in­vestor in their cor­ner as well, which will now start grow­ing up a new pipeline of its own.

The biotech is Idor­sia, which start­ed trad­ing on the Swiss ex­change at 10 Swiss francs and then shot up 30%. And of course the phar­ma part­ner is J&J, which has now for­mal­ly fin­ished the ac­qui­si­tion of Acte­lion for $30 bil­lion, spawn­ing a new busi­ness unit — its sixth — with plans to start build­ing out its late-stage work in pul­monary ar­te­r­i­al hy­per­ten­sion with a ful­ly fledged dis­cov­ery and ear­ly re­search team work­ing on next-gen prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER